Loading...
•
Jun 30, 2024
Taysha Gene Therapies Q2 2024 Earnings Report
Taysha Gene Therapies reported financial results for the second quarter ended June 30, 2024, and provided a corporate update.
Key Takeaways
Taysha Gene Therapies reported a net loss of $20.9 million for the second quarter of 2024. The company's cash and cash equivalents totaled $172.7 million as of June 30, 2024, which is expected to support operations into the fourth quarter of 2026.
Presented encouraging preliminary data from the pediatric trial and longer-term data from the adolescent and adult trial of TSHA-102.
Dosed the first patient in the high dose cohort of the adolescent and adult trial, with TSHA-102 generally well tolerated as of the initial six-week assessment.
Received IDMC approval to proceed with dosing the second adolescent/adult and first pediatric patient in the high dose cohort of the REVEAL trials, scheduled for Q3 2024.
Completed a public follow-on offering with net proceeds of $76.8 million, extending the anticipated cash runway into Q4 2026.
Taysha Gene Therapies
Taysha Gene Therapies
Forward Guidance
Taysha Gene Therapies anticipates several milestones including dosing patients in cohort two of REVEAL trials and reporting safety and efficacy data in the first half of 2025.
Positive Outlook
- Dosing of the second patient in cohort two (high dose) scheduled for the third quarter of 2024.
- Safety and efficacy data from cohort two (n=3) and an update on safety and efficacy data from cohort one (n=2) expected in the first half of 2025.
- Dosing of the first patient in cohort two (high dose) scheduled for the third quarter of 2024.
- Safety and efficacy data from cohort two (n=3) and an update on safety and efficacy data from cohort one (n=2) expected in the first half of 2025.